CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: LYRM2 (ImmuneEditome ID:57226)

1. Gene summary of enriched editing regions for LYRM2

check button Gene summary
Gene informationGene symbol

LYRM2

Gene ID

57226

GeneSynonymsDJ122O8.2
GeneCytomap

6q15

GeneTypeprotein-coding
GeneDescriptionLYR motif-containing protein 2
GeneModificationdate20230329
UniprotIDQ9NU23;G3V136;E5RG38;E5RJK7
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr6:89634439-89635065:-ENST00000517396.4ENSG00000083099.9LYRM2ncRNA_exonicAluSz6,AluJochr6:89634439-89635065:-.alignment


Top

2. Tumor-specific enriched editing regions for LYRM2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr6:89634439-89635065:-BRCAEER3.0546e-15image
ENSG00000083099.9,LYRM2BRCAEAG5.7662e-16image
chr6:89634439-89635065:-COADEER2.1207e-03image
ENSG00000083099.9,LYRM2COADEAG3.1245e-03image
chr6:89634439-89635065:-HNSCEER8.2626e-07image
ENSG00000083099.9,LYRM2HNSCEAG1.0222e-06image
ENSG00000083099.9,LYRM2KICHEAG2.6170e-04image
chr6:89634439-89635065:-LUADEER8.5919e-07image
ENSG00000083099.9,LYRM2LUADEAG1.1884e-06image
chr6:89634439-89635065:-LUSCEER1.3052e-02image
ENSG00000083099.9,LYRM2LUSCEAG9.1621e-03image
chr6:89634439-89635065:-UCECEER2.9182e-02image
ENSG00000083099.9,LYRM2UCECEAG3.1488e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000083099.9,LYRM2KIRPPathEAG4.6485e-024.7818e-030.1819image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000083099.9,LYRM2LIHCEAG8.4273e-034.7959e-028.6480e-02image

Top

3. Enriched editing regions and immune related genes for LYRM2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr6:89634439-89635065:-UCECEERENSG00000138642,HERC60.45161.3189e-055.1927e-080.4049imageNELAVL1;FBL;HNRNPC;NOP56;U2AF2;UPF1NADendritic_cells_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr6:89634439-89635065:-UCECEERENSG00000137628,DDX600.43264.2867e-052.0963e-080.4157imageNELAVL1;FBL;NOP56;U2AF2;UPF1NADendritic_cells_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr6:89634439-89635065:-UCECEERENSG00000137959,IFI44L0.41821.0207e-046.5152e-080.4022imageNELAVL1;FBL;HNRNPC;NOP56;U2AF2IFI44LMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr6:89634439-89635065:-UCECEERENSG00000067066,SP1000.39493.2963e-043.8678e-080.4085imageNELAVL1;FBL;HNRNPC;U2AF2;UPF1SP100Macrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr6:89634439-89635065:-UCECEERENSG00000115267,IFIH10.38785.0474e-042.9229e-080.4118imageNELAVL1;FBL;HNRNPC;NOP56;U2AF2;UPF1IFIH1Dendritic_cells_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr6:89634439-89635065:-PAADEERENSG00000101187,SLCO4A10.38682.7924e-045.4498e-100.4450imageNELAVL1;FBL;HNRNPC;NOP56;U2AF2;UPF1NAT_cells_CD8GSVA_HALLMARK_GLYCOLYSIS
chr6:89634439-89635065:-TGCTEERENSG00000241685,ARPC1A0.56507.9424e-103.2167e-130.5528imageNELAVL1;FBL;HNRNPC;NOP56;TARBP2;U2AF2;UPF1NAB_cells_naiveGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr6:89634439-89635065:-TGCTEERENSG00000138646,HERC50.55889.2759e-101.3022e-090.4728imageNELAVL1;FBL;HNRNPC;NOP56;TARBP2;U2AF2;UPF1HERC5Macrophages_M2GSVA_HALLMARK_ANGIOGENESIS
chr6:89634439-89635065:-TGCTEERENSG00000066248,NGEF0.53672.8521e-095.1721e-100.4828imageNELAVL1;FBL;HNRNPC;NOP56;TARBP2;U2AF2;UPF1NGEFB_cells_naiveGSVA_HALLMARK_ANGIOGENESIS
chr6:89634439-89635065:-TGCTEERENSG00000101347,SAMHD10.54275.1053e-091.6904e-110.5172imageNELAVL1;FBL;HNRNPC;NOP56;TARBP2;U2AF2;UPF1SAMHD1Macrophages_M2GSVA_HALLMARK_ANGIOGENESIS

More results



Top

4. Enriched editing regions and immune related splicing for LYRM2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr6:89634439-89635065:-
ESCAEERIRENSG00000168071.17chr1164352726:64352887:64353053:643532400.29631.9826e-026.9187e-070.4253imageNELAVL1;FBL;HNRNPC;NOP56;U2AF2NAMacrophages_M0GSVA_HALLMARK_ALLOGRAFT_REJECTION
ENSG00000083099.9,LYRM2
ESCAEAGIRENSG00000168071.17chr1164352726:64352887:64353053:643532400.30471.6650e-021.7504e-070.4452imageNADAR;AIFM1;CPSF6;CSTF2T;DDX3X;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;NOP56;NUMA1;PRPF8;RBFOX2;SAFB2;SF3B4;SLTM;SND1;SRSF1;TAF15;TARDBP;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;XRN2;ZNF184NAMacrophages_M0GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr6:89634439-89635065:-
GBMEERESENSG00000074054.13chr2121430072:121430177:121445448:121445496:121447336:1214475070.31551.4621e-039.5050e-070.4334imageNELAVL1;FBL;HNRNPC;NOP56;TARBP2;U2AF2;UPF1NAMacrophages_M0GSVA_HALLMARK_BILE_ACID_METABOLISM
ENSG00000083099.9,LYRM2
GBMEAGESENSG00000074054.13chr2121430072:121430177:121445448:121445496:121447336:1214475070.31681.5973e-038.0625e-070.4359imageNACIN1;ADAR;AIFM1;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF10;SRSF7;TAF15;TARDBP;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAMacrophages_M0GSVA_HALLMARK_BILE_ACID_METABOLISM
ENSG00000083099.9,LYRM2
KIRPEAGIRENSG00000100490.5chr1450329591:50332432:50334564:50334621-0.28601.0507e-053.4601e-09-0.4063imageNADAR;CNBP;CSTF2T;DDX3X;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LIN28;LSM11;MOV10;NOP56;NOP58;NUMA1;PRPF8;PTBP1;RBFOX2;RBM10;RBM47;SLTM;SND1;SRSF1;TAF15;TARDBP;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1NAMast_cells_restingGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr6:89634439-89635065:-
PAADEERESENSG00000072849.6chr175480123:5480144:5480386:5480543:5481100:5481139-0.34996.9635e-034.8555e-08-0.4092imageNELAVL1;FBL;HNRNPC;NOP56;U2AF2;UPF1NAMacrophages_M0GSVA_HALLMARK_P53_PATHWAY
ENSG00000083099.9,LYRM2
PAADEAGESENSG00000072849.6chr175480123:5480144:5480386:5480543:5481100:5481139-0.34597.5913e-035.3907e-08-0.4079imageNACIN1;AIFM1;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF7;TAF15;TARDBP;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAMacrophages_M0GSVA_HALLMARK_P53_PATHWAY
ENSG00000083099.9,LYRM2
PCPGEAGIRENSG00000102890.10chr1667202626:67203004:67203118:67203223-0.26669.9768e-031.5762e-06-0.4052imageNADAR;AIFM1;BUD13;CPSF6;CSTF2T;DDX54;DGCR8;DICER1;EIF4A3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP2;IGF2BP3;LIN28B;LSM11;NOP58;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF7;TAF15;TARDBP;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;XRN2;ZNF184ELMO3Mast_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr6:89634439-89635065:-
PCPGEERIRENSG00000102890.10chr1667202626:67203004:67203118:67203223-0.26491.1796e-021.7263e-06-0.4038imageNFBL;HNRNPC;U2AF2ELMO3Mast_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr6:89634439-89635065:-
SKCMEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.41998.3338e-151.2655e-18-0.4053imageNELAVL1;FBL;HNRNPC;NOP56;TARBP2;U2AF2;UPF1PRKCSHT_cells_CD8GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

More results



Top

5. Enriched editing regions and immune infiltration for LYRM2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr6:89634439-89635065:-ACCEERT_cells_CD4_memory_resting4.1291e-03-0.3387image
ENSG00000083099.9,LYRM2ACCEAGT_cells_CD4_memory_resting3.8439e-03-0.3412image
chr6:89634439-89635065:-BLCAEERT_cells_CD4_memory_activated2.2588e-050.2139image
ENSG00000083099.9,LYRM2BLCAEAGT_cells_CD4_memory_activated1.3057e-050.2199image
chr6:89634439-89635065:-BRCAEERMacrophages_M13.8429e-040.1083image
ENSG00000083099.9,LYRM2BRCAEAGMacrophages_M13.9317e-040.1081image
chr6:89634439-89635065:-CESCEERB_cells_naive8.8042e-04-0.1911image
ENSG00000083099.9,LYRM2CESCEAGB_cells_naive9.2463e-04-0.1903image
chr6:89634439-89635065:-CHOLEERNK_cells_activated3.5669e-020.3563image
ENSG00000083099.9,LYRM2CHOLEAGNK_cells_activated3.5669e-020.3563image
chr6:89634439-89635065:-COADEERB_cells_naive1.6707e-03-0.1936image
ENSG00000083099.9,LYRM2COADEAGB_cells_naive1.4661e-03-0.1959image
ENSG00000083099.9,LYRM2DLBCEAGMacrophages_M22.1566e-020.3456image
chr6:89634439-89635065:-ESCAEERMacrophages_M23.5712e-030.2291image
ENSG00000083099.9,LYRM2ESCAEAGMacrophages_M22.8198e-030.2347image
chr6:89634439-89635065:-GBMEERMacrophages_M01.3450e-02-0.1915image
ENSG00000083099.9,LYRM2GBMEAGMacrophages_M01.4250e-02-0.1899image
chr6:89634439-89635065:-HNSCEERB_cells_memory1.6712e-02-0.1091image
ENSG00000083099.9,LYRM2HNSCEAGB_cells_memory1.6225e-02-0.1096image
chr6:89634439-89635065:-KIRCEERT_cells_CD85.0322e-030.1440image
ENSG00000083099.9,LYRM2KIRCEAGMacrophages_M16.0568e-030.1409image
ENSG00000083099.9,LYRM2KIRPEAGMast_cells_resting4.3759e-04-0.2145image
ENSG00000083099.9,LYRM2LAMLEAGT_cells_CD81.3768e-020.3065image
chr6:89634439-89635065:-LGGEERMonocytes1.1002e-040.1677image
ENSG00000083099.9,LYRM2LGGEAGMonocytes1.2684e-040.1662image
chr6:89634439-89635065:-LIHCEERMacrophages_M15.0054e-040.1830image
ENSG00000083099.9,LYRM2LIHCEAGMacrophages_M14.5235e-040.1844image
chr6:89634439-89635065:-LUADEERDendritic_cells_resting9.1440e-04-0.1474image
ENSG00000083099.9,LYRM2LUADEAGDendritic_cells_resting6.6418e-04-0.1513image
chr6:89634439-89635065:-LUSCEERT_cells_CD4_memory_activated8.6539e-040.1494image
ENSG00000083099.9,LYRM2LUSCEAGT_cells_CD4_memory_activated9.5984e-040.1481image
chr6:89634439-89635065:-OVEERMacrophages_M18.3630e-040.1965image
ENSG00000083099.9,LYRM2OVEAGMacrophages_M11.1739e-030.1910image
chr6:89634439-89635065:-PAADEERMacrophages_M02.6406e-020.1669image
ENSG00000083099.9,LYRM2PAADEAGMacrophages_M02.3112e-020.1707image
chr6:89634439-89635065:-PCPGEERT_cells_CD82.6935e-030.2206image
ENSG00000083099.9,LYRM2PCPGEAGT_cells_CD82.8205e-030.2196image
chr6:89634439-89635065:-PRADEERT_cells_regulatory_(Tregs)4.2749e-050.1851image
ENSG00000083099.9,LYRM2PRADEAGT_cells_regulatory_(Tregs)1.1164e-040.1747image
chr6:89634439-89635065:-READEERT_cells_CD4_naive2.8186e-020.2327image
ENSG00000083099.9,LYRM2READEAGT_cells_CD4_naive2.7920e-020.2331image
chr6:89634439-89635065:-SARCEERNK_cells_resting1.1588e-02-0.1588image
ENSG00000083099.9,LYRM2SARCEAGNK_cells_resting1.1958e-02-0.1581image
chr6:89634439-89635065:-SKCMEERT_cells_CD81.3123e-050.2070image
ENSG00000083099.9,LYRM2SKCMEAGT_cells_CD81.3597e-050.2067image
chr6:89634439-89635065:-STADEERT_cells_CD84.0567e-060.2438image
ENSG00000083099.9,LYRM2STADEAGT_cells_CD82.4138e-050.2236image
chr6:89634439-89635065:-TGCTEERMacrophages_M29.5786e-08-0.4215image
ENSG00000083099.9,LYRM2TGCTEAGMacrophages_M29.5786e-08-0.4215image
chr6:89634439-89635065:-THCAEERT_cells_regulatory_(Tregs)1.2893e-030.1431image
ENSG00000083099.9,LYRM2THCAEAGT_cells_regulatory_(Tregs)1.3314e-030.1427image
chr6:89634439-89635065:-THYMEERT_cells_regulatory_(Tregs)5.3081e-05-0.3691image
ENSG00000083099.9,LYRM2THYMEAGT_cells_regulatory_(Tregs)5.1305e-05-0.3698image
chr6:89634439-89635065:-UCECEERDendritic_cells_activated2.9498e-040.2759image
ENSG00000083099.9,LYRM2UCECEAGDendritic_cells_activated2.5557e-040.2786image
chr6:89634439-89635065:-UCSEERMast_cells_activated2.2980e-020.3119image
ENSG00000083099.9,LYRM2UCSEAGMast_cells_activated2.3084e-020.3117image
ENSG00000083099.9,LYRM2UVMEAGT_cells_regulatory_(Tregs)3.2492e-020.2765image


Top

6. Enriched editing regions and immune gene sets for LYRM2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr6:89634439-89635065:-LIHCEER1.2642e-02-0.13178.3595e-03-0.13921.8236e-03-0.16424.0986e-020.1081image
chr6:89634439-89635065:-PAADEER7.0349e-030.20193.2994e-020.16043.1651e-030.22063.8850e-030.2160image
ENSG00000083099.9,LYRM2PAADEAG8.1675e-030.19823.9411e-020.15503.6446e-030.21744.7510e-030.2113image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr6:89634439-89635065:-ACCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER4.9173e-02-0.2360image
ENSG00000083099.9,LYRM2BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG8.8346e-070.2471image
chr6:89634439-89635065:-BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.1569e-060.2445image
chr6:89634439-89635065:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.5590e-210.2804image
ENSG00000083099.9,LYRM2BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.1937e-200.2793image
ENSG00000083099.9,LYRM2CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.0884e-030.1877image
chr6:89634439-89635065:-CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.0330e-030.1885image
ENSG00000083099.9,LYRM2CHOLGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG8.0143e-03-0.4410image
chr6:89634439-89635065:-CHOLGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER8.0143e-03-0.4410image
chr6:89634439-89635065:-COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER9.6746e-070.2977image
ENSG00000083099.9,LYRM2COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.9524e-060.2896image
ENSG00000083099.9,LYRM2DLBCGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.1821e-02-0.3450image
ENSG00000083099.9,LYRM2ESCAGSVA_HALLMARK_HYPOXIAEAG1.2204e-020.1977image
chr6:89634439-89635065:-ESCAGSVA_HALLMARK_HYPOXIAEER1.0571e-020.2016image
ENSG00000083099.9,LYRM2GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.0727e-050.3343image
chr6:89634439-89635065:-GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.7287e-060.3375image
ENSG00000083099.9,LYRM2HNSCGSVA_HALLMARK_HYPOXIAEAG5.3107e-040.1574image
chr6:89634439-89635065:-HNSCGSVA_HALLMARK_HYPOXIAEER7.1793e-040.1537image
ENSG00000083099.9,LYRM2KICHGSVA_HALLMARK_PEROXISOMEEAG1.4239e-02-0.3259image
ENSG00000083099.9,LYRM2KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.0478e-040.1716image
chr6:89634439-89635065:-KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.8584e-040.1720image
ENSG00000083099.9,LYRM2KIRPGSVA_HALLMARK_UV_RESPONSE_UPEAG3.5330e-070.3067image
chr6:89634439-89635065:-LGGGSVA_HALLMARK_MYC_TARGETS_V2EER1.2676e-14-0.3273image
ENSG00000083099.9,LYRM2LGGGSVA_HALLMARK_MYC_TARGETS_V2EAG1.5007e-14-0.3264image
ENSG00000083099.9,LYRM2LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.2364e-050.2178image
chr6:89634439-89635065:-LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER4.6889e-050.2134image
chr6:89634439-89635065:-LUADGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.1837e-04-0.1708image
ENSG00000083099.9,LYRM2LUADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.5325e-04-0.1680image
chr6:89634439-89635065:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.2730e-080.2405image
ENSG00000083099.9,LYRM2LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.9231e-080.2387image
chr6:89634439-89635065:-MESOGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.9703e-050.4450image
ENSG00000083099.9,LYRM2MESOGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.2393e-050.4436image
chr6:89634439-89635065:-OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.1438e-090.3326image
ENSG00000083099.9,LYRM2OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.1264e-090.3368image
ENSG00000083099.9,LYRM2PAADGSVA_HALLMARK_P53_PATHWAYEAG1.1880e-030.2418image
chr6:89634439-89635065:-PAADGSVA_HALLMARK_P53_PATHWAYEER9.5316e-040.2462image
chr6:89634439-89635065:-PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.6414e-030.2312image
ENSG00000083099.9,LYRM2PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.9464e-030.2276image
chr6:89634439-89635065:-PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.8852e-060.2148image
ENSG00000083099.9,LYRM2PRADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.4095e-060.2093image
chr6:89634439-89635065:-READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER8.2518e-030.2784image
ENSG00000083099.9,LYRM2READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.0734e-020.2692image
ENSG00000083099.9,LYRM2SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.1559e-030.1800image
chr6:89634439-89635065:-SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6933e-030.1883image
ENSG00000083099.9,LYRM2SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.7434e-080.2622image
chr6:89634439-89635065:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.0249e-080.2614image
ENSG00000083099.9,LYRM2STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.3895e-040.1796image
chr6:89634439-89635065:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.9930e-040.1979image
ENSG00000083099.9,LYRM2TGCTGSVA_HALLMARK_ANGIOGENESISEAG1.2100e-07-0.4184image
chr6:89634439-89635065:-TGCTGSVA_HALLMARK_ANGIOGENESISEER1.2100e-07-0.4184image
chr6:89634439-89635065:-THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.2605e-070.2283image
ENSG00000083099.9,LYRM2THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.6474e-070.2308image
chr6:89634439-89635065:-THYMGSVA_HALLMARK_HYPOXIAEER2.2847e-050.3855image
ENSG00000083099.9,LYRM2THYMGSVA_HALLMARK_HYPOXIAEAG2.3413e-050.3850image
ENSG00000083099.9,LYRM2UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.8721e-060.3520image
chr6:89634439-89635065:-UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.3798e-060.3548image
ENSG00000083099.9,LYRM2UCSGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.0267e-020.3497image
chr6:89634439-89635065:-UCSGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.0080e-020.3505image
ENSG00000083099.9,LYRM2UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.3182e-040.4737image


Top

7. Enriched editing regions and drugs for LYRM2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000083099.9,LYRM2ACCAMG.706EAG1.4613e-020.2908image
chr6:89634439-89635065:-ACCAMG.706EER1.3886e-020.2928image
chr6:89634439-89635065:-BLCACMKEER5.4697e-08-0.2723image
ENSG00000083099.9,LYRM2BLCACMKEAG3.2391e-07-0.2565image
chr6:89634439-89635065:-BRCAJNK.Inhibitor.VIIIEER5.8603e-09-0.1767image
ENSG00000083099.9,LYRM2BRCAJNK.Inhibitor.VIIIEAG9.5048e-09-0.1743image
ENSG00000083099.9,LYRM2CESCErlotinibEAG8.0890e-05-0.2256image
chr6:89634439-89635065:-CESCErlotinibEER7.8767e-05-0.2259image
ENSG00000083099.9,LYRM2COADGefitinibEAG8.7950e-04-0.2047image
chr6:89634439-89635065:-COADMetforminEER5.2417e-04-0.2132image
ENSG00000083099.9,LYRM2DLBCAZD.2281EAG2.0911e-02-0.3473image
chr6:89634439-89635065:-ESCABexaroteneEER5.6284e-04-0.2697image
ENSG00000083099.9,LYRM2ESCABexaroteneEAG5.7422e-04-0.2693image
chr6:89634439-89635065:-GBMBIBW2992EER2.2222e-06-0.3578image
ENSG00000083099.9,LYRM2GBMBIBW2992EAG2.1307e-06-0.3584image
ENSG00000083099.9,LYRM2HNSCGefitinibEAG1.9296e-06-0.2175image
chr6:89634439-89635065:-HNSCGefitinibEER4.6371e-07-0.2300image
ENSG00000083099.9,LYRM2KICHLenalidomideEAG7.6070e-03-0.3531image
ENSG00000083099.9,LYRM2KIRCATRAEAG1.5727e-04-0.1932image
chr6:89634439-89635065:-KIRCATRAEER1.3857e-04-0.1948image
ENSG00000083099.9,LYRM2KIRPEHT.1864EAG6.3157e-060.2734image
ENSG00000083099.9,LYRM2LAMLCisplatinEAG4.9736e-020.2463image
chr6:89634439-89635065:-LGGEpothilone.BEER3.8688e-210.3951image
ENSG00000083099.9,LYRM2LGGEpothilone.BEAG3.5224e-210.3955image
ENSG00000083099.9,LYRM2LIHCBleomycinEAG3.0425e-050.2206image
chr6:89634439-89635065:-LIHCBleomycinEER5.5214e-050.2135image
chr6:89634439-89635065:-LUADCHIR.99021EER1.2022e-020.1121image
ENSG00000083099.9,LYRM2LUADCHIR.99021EAG1.4953e-020.1087image
chr6:89634439-89635065:-LUSCCI.1040EER9.0418e-04-0.1489image
ENSG00000083099.9,LYRM2LUSCCI.1040EAG9.6944e-04-0.1480image
ENSG00000083099.9,LYRM2MESOCGP.082996EAG1.2353e-03-0.3571image
chr6:89634439-89635065:-MESOCGP.082996EER1.4081e-03-0.3532image
chr6:89634439-89635065:-OVBIBW2992EER4.0119e-04-0.2079image
ENSG00000083099.9,LYRM2OVAZD8055EAG2.6647e-040.2140image
ENSG00000083099.9,LYRM2PAADAZD7762EAG5.0399e-030.2129image
chr6:89634439-89635065:-PAADAZD7762EER4.5720e-030.2152image
ENSG00000083099.9,LYRM2PCPGBryostatin.1EAG1.2315e-050.3170image
chr6:89634439-89635065:-PCPGBryostatin.1EER1.1765e-050.3177image
ENSG00000083099.9,LYRM2PRADBortezomibEAG1.2277e-06-0.2184image
chr6:89634439-89635065:-PRADBortezomibEER4.3703e-06-0.2073image
chr6:89634439-89635065:-READAMG.706EER2.2247e-040.3839image
ENSG00000083099.9,LYRM2READAMG.706EAG2.0040e-040.3864image
chr6:89634439-89635065:-SARCAG.014699EER3.6527e-030.1825image
ENSG00000083099.9,LYRM2SARCAG.014699EAG3.2741e-030.1846image
ENSG00000083099.9,LYRM2SKCMAZD6244EAG7.7626e-08-0.2538image
chr6:89634439-89635065:-SKCMCI.1040EER1.6081e-07-0.2477image
ENSG00000083099.9,LYRM2STADCI.1040EAG1.1252e-05-0.2323image
chr6:89634439-89635065:-STADCI.1040EER6.6849e-06-0.2384image
chr6:89634439-89635065:-TGCTGSK269962AEER1.7308e-070.4137image
ENSG00000083099.9,LYRM2TGCTGSK269962AEAG1.7308e-070.4137image
chr6:89634439-89635065:-THCAAMG.706EER3.1190e-090.2603image
ENSG00000083099.9,LYRM2THCAAMG.706EAG2.1227e-090.2629image
chr6:89634439-89635065:-THYMABT.263EER1.5949e-070.4673image
ENSG00000083099.9,LYRM2THYMABT.263EAG1.8465e-070.4652image
ENSG00000083099.9,LYRM2UCECAMG.706EAG1.0936e-030.2498image
chr6:89634439-89635065:-UCECAMG.706EER1.3965e-030.2446image
chr6:89634439-89635065:-UCSCMKEER2.3611e-040.4846image
ENSG00000083099.9,LYRM2UCSCMKEAG2.3650e-040.4845image
ENSG00000083099.9,LYRM2UVMEtoposideEAG1.1390e-030.4100image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType